Tower Research Capital (TRC)’s Tonix Pharmaceuticals TNXP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.69K | Sell |
289
-889
| -75% | -$11.5K | ﹤0.01% | 4494 |
|
|
2026
Q1 | $16.2K | Sell |
1,178
-247
| -17% | -$3.8K | ﹤0.01% | 3626 |
|
|
2025
Q4 | $22.3K | Sell |
1,425
-2,034
| -59% | -$37.5K | ﹤0.01% | 3017 |
|
|
2025
Q3 | $83.6K | Sell |
3,459
-3,713
| -52% | -$138K | ﹤0.01% | 2144 |
|
|
2025
Q2 | $258K | Buy |
7,172
+3,731
| +108% | +$97.8K | 0.01% | 1554 |
|
|
2025
Q1 | $61.5K | Buy |
+3,441
| New | +$69.8K | ﹤0.01% | 2083 |
|
|
2024
Q4 | – | Sell |
-356
| Closed | -$5.3K | – | 6005 |
|
|
2024
Q3 | $5.3K | Buy |
356
+306
| +612% | +$12.3K | ﹤0.01% | 4293 |
|
|
2024
Q2 | $3.51K | Buy |
50
+39
| +355% | +$17.7K | ﹤0.01% | 4879 |
|
|
2024
Q1 | $6.4K | Buy |
+11
| New | +$11.8K | ﹤0.01% | 4378 |
|
|
2022
Q4 | – | Sell |
-1
| Closed | -$6K | – | 6378 |
|
|
2022
Q3 | $6K | Buy |
+1
| New | +$24.5K | ﹤0.01% | 5058 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 4313 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 3647 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 4611 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 4675 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 3611 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 4435 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 4294 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 4274 |
|
|
2017
Q2 | – | Hold |
0
| – | -$11K | – | 3442 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 1718 |
|
|
2016
Q3 | – | Hold |
0
| – | -$1K | – | 4443 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 4218 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 2410 |
|
|
2015
Q3 | – | Hold |
0
| – | -$3K | – | 4763 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 3585 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 3826 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 3160 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 4157 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 3759 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 3912 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 2686 |
|
|
2013
Q3 | – | Hold |
0
| – | – | – | 3971 |
|
Other funds holding TNXP
JHC
II
Tower Research Capital (TRC)'s TNXP Position: Q2 2026 in Review
Tower Research Capital (TRC) reduced its Tonix Pharmaceuticals (TNXP) stake by 75% in Q2 2026, selling an estimated $11.5K and leaving 289 shares worth $3.69K. The position accounts for ﹤0.01% of the portfolio, ranked #4494.
Tower Research Capital (TRC) first reported a position in TNXP in Q3 2022 and has held it in 10 quarters since. The position peaked at $258K in Q2 2025. 102 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.
- Tower Research Capital (TRC) held 289 shares of Tonix Pharmaceuticals worth $3.69K as of Q2 2026.
- Tower Research Capital (TRC) sold 889 Tonix Pharmaceuticals shares in Q2 2026, an estimated $11.5K.
- Tonix Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4494 holding.
- Tower Research Capital (TRC) first reported a position in Tonix Pharmaceuticals in Q3 2022 and has held it in 10 quarters since.
- Tower Research Capital (TRC)'s Tonix Pharmaceuticals position peaked at $258K in Q2 2025.
- 102 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.